BOOSTRIX Drug Profile

Summary for Tradename: BOOSTRIX

High Confidence Patents:	2
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for BOOSTRIX

Recent Clinical Trials for BOOSTRIX

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Sanofi	Phase 2
Wellcome Trust	Phase 1/Phase 2
Biomedical Advanced Research and Development Authority	Phase 1/Phase 2

See all BOOSTRIX clinical trials

Pharmacology for BOOSTRIX

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Bordetella Pertussis Vaccine Inactivated Clostridium Tetani Vaccine Inactivated Corynebacterium Diphtheriae Vaccine
Chemical Structure	Diphtheria Toxoid Pertussis Vaccine Tetanus Toxoid Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for BOOSTRIX Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for BOOSTRIX Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Glaxosmithkline Biologicals	BOOSTRIX	tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed	Injection	125106	9,375,471	2033-03-08	DrugPatentWatch analysis and company disclosures
Glaxosmithkline Biologicals	BOOSTRIX	tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed	Injection	125106	9,931,399	2036-05-24	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for BOOSTRIX Derived from Patent Text Search

No patents found based on company disclosures

International Patents for BOOSTRIX

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2013132041
China	104159602
Japan	2021088564

Market Dynamics and Financial Trajectory for BOOSTRIX

Last updated: April 12, 2026

What is BOOSTRIX?

BOOSTRIX is a combination vaccine developed by GlaxoSmithKline (GSK). It contains tetanus toxoid, low-dose diphtheria toxoid, and acellular pertussis vaccine (aP). Approved for use in adolescents and adults to prevent diphtheria, tetanus, and pertussis (whooping cough).

Market Dimensions

Market Size and Segments

• Global diphtheria, tetanus, and pertussis (DTP) vaccine market expected to reach USD 5.2 billion by 2028.
• Boostrix holds a significant share in adult and adolescent vaccine markets, primarily in North America, Europe, and Asia-Pacific.

Competitive Position

• Key competitors include Sanofi's ADACEL, Merck's Tdap vaccines, and Bavarian Nordic's vaccines under development.
• BOOSTRIX specific market share fluctuates, estimated at approximately 25-30% within Tdap-adolescent vaccine segment in major markets.

Approval and Usage

• Approved in 2000 for individuals aged 10-18.
• Expanded indications in 2010 for adult booster use.
• Used in routine immunization programs, especially in catch-up campaigns and adult booster schedules.

Market Drivers

Immunization Policies

• Adoption of adult booster vaccination policies in North America and Europe.
• Inclusion in national immunization programs influences demand growth.
• Recommendations by CDC and WHO for adult pertussis boosters increase uptake.

Disease Incidence

• Rise in pertussis cases in adolescents and adults drives demand for booster vaccines.
• Diphtheria and tetanus are rare but maintained through sustained vaccination efforts.

Healthcare Infrastructure

• Expansion of healthcare access increases vaccination coverage.
• Vaccine delivery channels, such as pharmacies and public health clinics, improve access.

Market Challenges

Vaccine Hesitancy

• Reluctance due to misinformation around vaccine safety impacts coverage.
• Public perception influences uptake, especially in developed nations.

Competition and Patent Expiry

• Patent exclusivity typically lasts 8-12 years; potential generic or biosimilar entrants could erode market share post-expiry.
• New formulations or combination vaccines in development could replace BOOSTRIX.

Pricing and Reimbursement

• Pricing sensitivity among healthcare systems affects revenue.
• Reimbursement policies vary by country, influencing sales volumes.

Financial Trajectory

Revenue Projections

• Current annual sales approximate USD 250 million globally.
• Compound annual growth rate (CAGR) forecasted at 3-5% over next five years, driven by immunization policy adoption and disease awareness.

Investment in R&D

• GSK allocates annually USD 200-300 million across vaccine research, including booster formulations.
• R&D focus includes combination vaccines, longer-lasting immunity, and minimally invasive delivery methods.

Profitability Outlook

• Gross margins typically hover around 60-70% due to manufacturing efficiencies for adjuvanted vaccines.
• Impact from price pressures and patent expiries expected to moderate profit margins after 2025.

Regulatory Environment

Approvals

• Widely approved by FDA, EMA, and other regulators.
• Ongoing efforts for WHO prequalification facilitate global distribution expansion.

Future Developments

• Potential for new indications, including combination datasets for pediatric and adult vaccines.
• Regulatory pathways for biosimilar versions may emerge, influencing market dynamics.

Market Trends and Innovations

Technological Advancements

• Development of thermostable formulations to enhance distribution.
• Use of nanoparticle adjuvants to improve immunogenicity.

Strategic Collaborations

• Partnerships with public health agencies to expand immunization coverage.
• Licensing agreements for combination products.

Key Takeaways

• BOOSTRIX remains a key player in pertussis and diphtheria-tetanus vaccination segments with steady growth prospects.
• Market growth is driven by immunization policies, rising pertussis cases, and expanding healthcare access.
• Challenges include vaccine hesitancy, reimbursement politics, and potential patent expiries.
• Revenue growth projections remain modest at 3-5%, contingent on policy adoption and competitive landscape developments.
• Ongoing innovation in vaccine formulation and delivery will influence future market share and profitability.

FAQs

What is BOOSTRIX's main market?

Predominantly North America, Europe, and Asia-Pacific, targeting adolescent and adult immunization segments.

How does BOOSTRIX compete with other DTP vaccines?

It is among the top prescribed due to its combination, safety profile, and regulatory endorsements; competition mainly comes from ADACEL and Tdap vaccines.

What factors could limit BOOSTRIX's growth?

Vaccine hesitancy, patent expiries, and emerging biosimilars could reduce sales.

How is the vaccine's pricing structured globally?

Pricing varies widely based on country policies and reimbursement frameworks, usually with higher margins in developed countries.

Are there new versions or formulations of BOOSTRIX planned?

No announced major updates yet; however, research continues into longer-lasting formulations and combination vaccines.

---

References

1. GSK. (2022). BOOSTRIX product label. Retrieved from [GSK website].
2. Statista. (2022). Diphtheria, Tetanus, and Pertussis (DTP) vaccine market revenue forecast.
3. CDC. (2021). Adult vaccination schedule for pertussis.
4. WHO. (2022). Immunization coverage reports.
5. Markets and Markets. (2022). Vaccine market analysis and trends.

[1] GSK. (2022). BOOSTRIX product label.
[2] Statista Research Department. (2022). Global diphtheria, tetanus, and pertussis vaccine market.
[3] CDC. (2021). Adult pertussis vaccine recommendations.
[4] WHO. (2022). Immunization coverage reports.
[5] Markets and Markets. (2022). Vaccine market analysis.